Eli Lilly and Company (NYSE:LLY) will release earnings for its first quarter before the opening bell on Thursday, April 30.

Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings of $6.79 per share. That’s up from $3.34 per share in the year-ago period. The consensus estimate for Eli Lilly's quarterly revenue is $17.8 billion (it reported $12.73 billion last year), according to Benzinga Pro.

As per the recent news, Profluent has entered a multi-program strategic research collaboration with Eli Lilly to develop and commercialize custom site-specific recombinases to treat genetic diseases.

Shares of Eli Lilly fell 2.6% to close at $851.21 on Wednesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • Guggenheim analyst Seamus Fernandez maintained a Buy rating and raised the price target from $1,163 to $1,183 on April 22, 2026. This analyst has an accuracy rate of 80%.
  • Morgan Stanley analyst Terence Flynn maintained the stock with an Overweight rating and increased the price target from $1,313 to $1,327 on April 10, 2026. This analyst has an accuracy rate of 69%.
  • B of A Securities analyst Jason Gerberry maintained the stock with a Buy and raised the price target from $1,293 to $1,294 on April 2, 2026. This analyst has an accuracy rate of 69%.
  • HSBC analyst Rajesh Kumar downgraded the stock from Hold to Reduce and slashed the price target from $1,070 to $850 on March 17, 2026. This analyst has an accuracy rate of 50%.
  • RBC Capital analyst Trung Huynh initiated coverage on the stock with an Outperform rating and announced a price target of $1,250 on Feb. 25, 2026. This analyst has an accuracy rate of 69%

Considering buying LLY stock? Here’s what analysts think:

Photo via Shutterstock